Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186537 · ClinicalTrials.gov registry record · NA
Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
NCT00186537: Completed NA study, sponsored by Stanford University.
NCT00186537 is a NA study that has completed, run by Stanford University. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186537, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
Study Summary
Approximately 1/4 of the US population has insulin resistance and the associated risk factors such as elevated lipid levels -triglycerides (type of fat from what we eat and what the liver produces and low HDL cholesterol which is the good cholesterol helping to protect against heart disease. Currently one known treatment for this a medication called fenofibrate, another medication that can improve insulin resistance is rosiglitazone, a third treatment known to improve insulin resistance an decrease triglycerides is weight loss. In this study insulin resistant individuals with elevated triglycerides and or a ratio of triglycerides to HDL cholesterol of 3:1 or greater will be randomized (selected by chance) to receive one of these treatments and results of insulin sensitivity and cardiac risk profiles will be compared at the end of the study.
Interventions
- DRUG Rosiglitazone
- DRUG Fenofibrate
- BEHAVIORAL Weight Loss
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2003-09 |
| Est. Completion | 2008-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186537
The ClinicalTrials.gov registry entry for NCT00186537 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rosiglitazone is the first listed.
NCT00186537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00186537 about?
NCT00186537 is a clinical study titled "Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.". Approximately 1/4 of the US population has insulin resistance and the associated risk factors such as elevated lipid levels -triglycerides (type of fat from what we eat and what the liver produces and low HDL cholesterol which is the good cholesterol helping to protect against heart disease. Current...
What is the current status of trial NCT00186537?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2003-09. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00186537?
The interventions under investigation include: Rosiglitazone (DRUG), Fenofibrate (DRUG), Weight Loss (BEHAVIORAL).
Who is sponsoring clinical trial NCT00186537?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.